Vir Biotechnology, Inc. Overview
Pro stress-test →Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company is positioning itself as a leader in masked T-cell engager immunotherapy while maintaining its hepatitis delta franchise.
Strategic Profile
Pro stress-test →The company has executed two landmark collaborations worth up to $2.2 billion combined. In April 2026, the global strategic collaboration with Astellas to advance the PSMA-targeted dual-masked T-cell engager VIR-5500 closed with the first patient dosed in Phase 1 dose-expansion cohorts. Strategic partnerships and financing have extended cash runway to 2028.
Competitive Landscape
Pro stress-test →Competitors include Rigel Pharmaceuticals, Allogene Therapeutics, Adaptimmune Therapeutics, Sorrento Therapeutics, and Synlogic. Vir differentiates itself through its dual masked T-cell engager platform across both infectious disease and oncology indications, with particularly strong clinical progress in hepatitis delta and prostate cancer.
Industry Context
Vir Biotechnology, Inc. operates in Immunology Drugs.
Key facts
Headquarters: San Francisco, US · Revenue: $64.7 million trailing twelve-month revenue as of March 31, 2026 · Market cap: $1.56 billion as of May 7, 2026